Glaukos Corporation
GKOS
Rank in Stocks
#2086
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Share Price
$166.79
Last synced: 2026-10-19
Market Cap
$9.84B
Change (1 day)
1.44%
Change (1 year)
109.88%
Country
US
Trade Glaukos Corporation (GKOS)
Category
Healthcare
Stock split history for Glaukos Corporation (GKOS)
Glaukos Corporation stock (symbol: GKOS) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One GKOS share bought prior to Oct 20, 2026 would equal to 0 GKOS shares today.
The most recent stock split occurred on Oct 20, 2026.
One GKOS share bought prior to Oct 20, 2026 would equal to 0 GKOS shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 9 | x285 |
US
|
|
| 7 | x127 |
IE
|
|
| 9 | x162 |
US
|
|
| 2 | x4 |
US
|
|
| 0 | - |
DE
|
